All In MedTech

Device Trial Radar · NCT07943702

Correlation Between Visual Reading and DOlab Software Quantitative Analysis of DaT-SPECT Images

Pre-market Clinical Investigation to Evaluate the Correlation Between Visual Interpretation and Quantitative Analysis Performed by DOlab Software - DaT-SPECT Workflow for the Identification of Neurological Disorders Related to Dopamine Transporter Dysfunction

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Oct 13, 2026

Primary completion

Jan 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Dorian Technologies S.r.l.Not on our public-company list
Sponsor type
Industry
Collaborators
JSB Solutions S.R.L.
First posted
Nov 17, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to find out whether the quantitative results of DOlab software (DaT-SPECT workflow) agree with the visual reading of brain scans performed by nuclear medicine physicians. The scans are 123I-ioflupane DaT-SPECT images of adults who were evaluated for dopamine transporter dysfunction, a condition seen in Parkinson's disease, other parkinsonian syndromes and dementia with Lewy bodies. The main questions it aims to answer are: * Do the visual scores given by expert readers (0 = normal to 3 = marked abnormality) correlate with the values calculated by the software? * Does using the software report change or refine the readers' classification compared with visual reading alone? * How usable do readers find the software? The study uses existing scans of 120 patients collected between January 2015 and May 2025 at two Italian hospitals. No new tests or treatments are given to participants, and the software results are not used for their clinical care.

Conditions

  • Parkinsonian Disorders
  • Parkinson Disease
  • Lewy Body Disease
  • Movement Disorders

Interventions

  • DOlab software - DaT-SPECT workflowDevice

    Investigational software (not CE-marked, class IIa) that automatically quantifies striatal 123I-ioflupane binding using four metrics (SBR, Southampton SBR, Basal Ganglia V3, Volume Fraction) and compares them with a PPMI-based normative database. It is applied retrospectively to existing images, and its output is not used for patient care.

  • Visual interpretation (comparator)Diagnostic test

    Visual reading of the same 123I-ioflupane images by blinded nuclear medicine physicians, scored 0-3 for the caudate, anterior putamen and posterior putamen of each hemisphere, according to the EANM/SNMMI guidelines.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Correlation between visual score and DOlab quantitative metricsTime frame: Phase 1 reading session, within 4 months of study start

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Azienda USL Toscana Centro - Ospedale Santo Stefano

    Prato, Tuscany, Italy · Recruiting

  • Azienda Ospedale Università Padova

    Padova, Veneto, Italy · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.